scispace - formally typeset
L

Licia Rivoltini

Researcher at University of Milan

Publications -  257
Citations -  22886

Licia Rivoltini is an academic researcher from University of Milan. The author has contributed to research in topics: Melanoma & Antigen. The author has an hindex of 75, co-authored 245 publications receiving 20829 citations. Previous affiliations of Licia Rivoltini include National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

TL;DR: A gene encoding a melanocyte lineage-specific protein (MART-1) that is a widely shared melanoma antigen recognized by the T lymphocytes of patients with established malignancy is identified and opens possibilities for the development of immunotherapies for patients with melanoma.
Journal ArticleDOI

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

TL;DR: One of the 9-mer peptides, AAGIGILTV, was most effective in sensitizing the T2 cells for TIL lysis and appears to be a very common immunogenic epitope for HLA-A2-restricted melanoma-specific TIL and may be useful for the development of immunotherapeutic strategies.
Journal ArticleDOI

Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.

TL;DR: The data provide evidence for a novel mechanism potentially operating in Fas tumor counterattack through the secretion of subcellular particles expressing functional FasL, which may form a sort of front line hindering lymphocytes and other immunocompetent cells from entering neoplastic lesions and exert their antitumor activity.
Journal ArticleDOI

Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor–Based Antitumor Vaccine

TL;DR: CD14+HLA-DR-/lo cells exerting TGF-beta-mediated immune suppression represent a new subset of MSC potentially expandable by the administration of GM-CSF-based vaccines in metastatic melanoma patients.